Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 29, 2015

Efficacy and Safety of Bosutinib After Failed TKI in Advanced Leukemia

American Journal of Hematology

 

Additional Info

American Journal of Hematology
Long-Term Efficacy and Safety of Bosutinib in Patients With Advanced Leukemia Following Resistance/Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors
Am. J. Hematol 2015 Jun 01;[EPub Ahead of Print], C Gambacorti-Passerini, HM Kantarjian, DW Kim, HJ Khoury, AG Turkina, TH Brümmendorf, E Matczak, N Bardy-Bouxin, M Shapiro, K Turnbull, E Leip, JE Cortes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading